

Aldona Kowalska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/309786/publications.pdf>

Version: 2024-02-01

60
papers

1,059
citations

430754

18
h-index

454834

30
g-index

61
all docs

61
docs citations

61
times ranked

1752
citing authors

#	ARTICLE	IF	CITATIONS
1	Genotoxicity Associated with ¹³¹ I and ^{99m} Tc Exposure in Nuclear Medicine Staff: A Physical and Biological Monitoring Study. <i>Cells</i> , 2022, 11, 1655.	1.8	1
2	Incidence of the CHEK2 Germline Mutation and Its Impact on Clinicopathological Features, Treatment Responses, and Disease Course in Patients with Papillary Thyroid Carcinoma. <i>Cancers</i> , 2021, 13, 470.	1.7	6
3	Is Male Sex A Prognostic Factor in Papillary Thyroid Cancer?. <i>Journal of Clinical Medicine</i> , 2021, 10, 2438.	1.0	6
4	Late-Onset Medullary Thyroid Cancer in a Patient with a Germline RET Codon C634R Mutation. <i>Diagnostics</i> , 2021, 11, 1448.	1.3	1
5	Immune Profiling of Medullary Thyroid Cancer—An Opportunity for Immunotherapy. <i>Genes</i> , 2021, 12, 1534.	1.0	7
6	Occurrence of Arrhythmias in Women with Thyroid Cancer Receiving Suppressive Doses of Levothyroxine. <i>Current Oncology</i> , 2021, 28, 5009-5018.	0.9	0
7	Snail-1 Overexpression Correlates with Metastatic Phenotype in BRAFV600E Positive Papillary Thyroid Carcinoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 2701.	1.0	7
8	Effective Preoperative Plasmapheresis Treatment of Severe Hyperthyroidism in a Patient with Giant Toxic Nodular Goiter and Methimazole-Induced Agranulocytosis. <i>Medicina (Lithuania)</i> , 2020, 56, 290.	0.8	10
9	The current state and future perspectives of high intensity focused ultrasound (HIFU) ablation for benign thyroid nodules. <i>Gland Surgery</i> , 2020, 9, S95-S104.	0.5	6
10	Does the TT Variant of the rs966423 Polymorphism in DIRC3 Affect the Stage and Clinical Course of Papillary Thyroid Cancer?. <i>Cancers</i> , 2020, 12, 423.	1.7	3
11	Histopathology and immunohistochemistry as prognostic factors for poorly differentiated thyroid cancer in a series of Polish patients. <i>PLoS ONE</i> , 2020, 15, e0229264.	1.1	5
12	Papillary Thyroid Cancer in a Struma Ovarii in a 17-Year-Old Nulliparous Patient: A Case Report. <i>Diagnostics</i> , 2020, 10, 45.	1.3	14
13	Did Introducing a New Category of Thyroid Tumors (Non-invasive Follicular Thyroid Neoplasm with) Tj ETQq1 1 0.784314 rgBT /Overl Bethesda System for Reporting Thyroid Cytopathology?. <i>Endocrine Pathology</i> , 2020, 31, 143-149.	5.2	7
14	Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a problematic entity. <i>Endocrine Connections</i> , 2020, 9, R47-R58.	0.8	15
15	Telomeres and telomerase in oncogenesis (Review). <i>Oncology Letters</i> , 2020, 20, 1015-1027.	0.8	59
16	Unusual case of radioactive iodine induced Graves disease with orbitopathy following total thyroidectomy in a patient with papillary thyroid microcarcinoma. <i>Endokrynologia Polska</i> , 2020, 71, 277-278.	0.3	1
17	Two cases of pheochromocytoma in pregnancy: a multidisciplinary challenge. <i>Endokrynologia Polska</i> , 2020, 71, 98-99.	0.3	0
18	Title is missing!. , 2020, 15, e0229264.		0

#	ARTICLE	IF	CITATIONS
19	Title is missing!. , 2020, 15, e0229264.		0
20	Title is missing!. , 2020, 15, e0229264.		0
21	Title is missing!. , 2020, 15, e0229264.		0
22	Impact of BRAF V600E and TERT Promoter Mutations on Response to Therapy in Papillary Thyroid Cancer. <i>Endocrinology</i> , 2019, 160, 2328-2338.	1.4	22
23	Current Knowledge of Germline Genetic Risk Factors for the Development of Non-Medullary Thyroid Cancer. <i>Genes</i> , 2019, 10, 482.	1.0	62
24	Coexisting Germline CHEK2 and Somatic BRAFV600E Mutations in Papillary Thyroid Cancer and Their Association with Clinicopathological Features and Disease Course. <i>Cancers</i> , 2019, 11, 1744.	1.7	21
25	Assessment of the nuclear medicine personnel occupational exposure to radioiodine. <i>European Journal of Radiology</i> , 2019, 121, 108712.	1.2	9
26	Poorly differentiated thyroid cancer in the context of the revised 2015 American Thyroid Association Guidelines and the Updated American Joint Committee on Cancer/Tumorâ€Nodeâ€Metastasis Staging System (eighth edition). <i>Clinical Endocrinology</i> , 2019, 91, 331-339.	1.2	9
27	The influence of the reclassification of NIFTP as an uncertain tumour on risk of malignancy for the diagnostic categories according to the Bethesda system for reporting thyroid cytopathology. <i>Endokrynologia Polska</i> , 2019, 70, 232-236.	0.3	4
28	Impact of non-invasive follicular thyroid neoplasms with papillary-like nuclear features on risk of malignancy. <i>European Journal of Endocrinology</i> , 2019, 181, L7-L8.	1.9	0
29	Measurement of 131I activity in air indoor Polish nuclear medical hospital as a tool for an internal dose assessment. <i>Radiation and Environmental Biophysics</i> , 2018, 57, 77-82.	0.6	10
30	The impact of BMI on clinical progress, response to treatment, and disease course in patients with differentiated thyroid cancer. <i>PLoS ONE</i> , 2018, 13, e0204668.	1.1	30
31	Long-acting FC-fusion rhGH (GX-H9) shows potential for up to twice-monthly administration in GH-deficient adults. <i>European Journal of Endocrinology</i> , 2018, 179, 169-179.	1.9	11
32	Rekomendacje Polskich Towarzystw Naukowych â€Diagnostyka i leczenie raka tarczycyâ€ Aktualizacja na rok 2018. <i>Endokrynologia Polska</i> , 2018, 69, 34-74.	0.3	32
33	Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5. <i>European Journal of Cancer</i> , 2017, 77, 140-152.	1.3	72
34	Delayed risk stratification system in pT1aNO/Nx DTC patients treated without radioactive iodine. <i>Endocrine Connections</i> , 2017, 6, 522-527.	0.8	8
35	Response to therapy of papillary thyroid cancer of known <i><sc>BRAF</sc></i> status. <i>Clinical Endocrinology</i> , 2017, 87, 815-824.	1.2	19
36	Immunohistochemistry cannot replace DNA analysis for evaluation of<i>BRAF</i>V600E mutations in papillary thyroid carcinoma. <i>Oncotarget</i> , 2017, 8, 74897-74909.	0.8	16

#	ARTICLE	IF	CITATIONS
37	Evaluation of molecular diagnostic approaches for the detection of BRAF p.V600E mutations in papillary thyroid cancer: Clinical implications. PLoS ONE, 2017, 12, e0179691.	1.1	9
38	The p.G534E variant of <i>HABP2</i> is not associated with sporadic papillary thyroid carcinoma in a Polish population. Oncotarget, 2017, 8, 58304-58308.	0.8	14
39	Zalecenia dotyczące...ce postępowania diagnostyczno-terapeutycznego w nowotworach neuroendokrynnych układu pokarmowego (rekomendowane przez Polsk... Sieć Guzów) Tj ETQq1 1 0.7843140rgBT /Overclock 10	0.3	20
40	Nowotwory neuroendokrynne ¼o...dka i dwunastnicy z uwzględnieniem gastrinoma (zasady postępowania) Tj ETQq0 0 0 rgBT /O	0.3	20
41	Nowotwory neuroendokrynne jelita cienkiego i wyrostka robaczkowego " zasady postępowania (rekomendowane przez Polsk... Sieć Guzów Neuroendokrynnych). Endokrynologia Polska, 2017, 68, 223-236.	0.3	18
42	Nowotwory neuroendokrynne jelita grubego " zasady postępowania (rekomendowane przez Polsk... Sieć) Tj ETQq0 0 0 rgBT /O	0.3	20
43	Diagnosis of thyroid tumours in Świętokrzyskie Province in Poland with respect to the regulations provided in the new oncological package. Pediaatria I Medycyna Rodzinna, 2017, 13, 491-497.	2.3	0
44	Repeated nondiagnostic result of thyroid fine-needle aspiration biopsy. Wspolczesna Onkologia, 2016, 6, 491-495.	0.7	4
45	Increase in Papillary Thyroid Cancer Incidence Is Accompanied by Changes in the Frequency of the <i>BRAF</i> ^{V600E} Mutation: A Single-Institution Study. Thyroid, 2016, 26, 543-551.	2.4	34
46	The Delayed Risk Stratification System in the Risk of Differentiated Thyroid Cancer Recurrence. PLoS ONE, 2016, 11, e0153242.	1.1	24
47	^{99m} Tc Labeled Glucagon-Like Peptide-1-Analogue (^{99m} Tc-GLP1) Scintigraphy in the Management of Patients with Occult Insulinoma. PLoS ONE, 2016, 11, e0160714.	1.1	30
48	Przydatność określenia obecności mutacji BRAF V600E w biopsji aspiracyjnej celowanej cienkoigłowej w zmianach niezdeteminowanych. Endokrynologia Polska, 2016, 67, 41-47.	0.3	8
49	The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer. PLoS ONE, 2015, 10, e0133852.	1.1	24
50	<i>CHEK2</i> mutations and the risk of papillary thyroid cancer. International Journal of Cancer, 2015, 137, 548-552.	2.3	97
51	Coexistence of macroprolactinaemia and hyperprolactinaemia in women with oligo-/amenorrhoea is associated with high risk of pituitary adenomas. Gynecological Endocrinology, 2014, 30, 385-387.	0.7	7
52	The <i>BRAF</i> ^{V600E} mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?. Clinical Endocrinology, 2014, 80, 899-904.	1.2	52
53	Wolne i biodostępne frakcje steroidów płciowych mogą... wpływać na kości u młodych mężczyzn w zależności od wieku i stężenia estradiolu. Endokrynologia Polska, 2014, 65, 357-364.	0.3	4
54	The role of ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan. Nuclear Medicine Review, 2014, 17, 87-93.	0.3	15

#	ARTICLE	IF	CITATIONS
55	Variation of the epidemiological structure of thyroid cancer between year 2000 and 2012. <i>Thyroid Research</i> , 2013, 6, .	0.7	4
56	Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 524-531.	3.3	96
57	Testing new susceptibility genes in the cohort of apparently sporadic pheochromocytoma/paraganglioma patients with clinical characteristics of hereditary syndromes. <i>Clinical Endocrinology</i> , 2013, 79, 817-823.	1.2	38
58	Prevalence of macroprolactinaemia in regularly menstruating women with non-toxic goitre or autoimmune thyroid disease. <i>Thyroid Research</i> , 2012, 5, 20.	0.7	1
59	The clinical course of poorly differentiated thyroid carcinoma (insular carcinoma) - own observations. <i>Endokrynologia Polska</i> , 2010, 61, 467-73.	0.3	14
60	High sensitivity of BRAF detection method does not alter response to therapy of papillary thyroid cancer of known BRAF status. <i>Endocrine Abstracts</i> , 0, , .	0.0	1